Treatment options for DOCK8 deficiency-related severe dermatitis.

Ayelet OllechJacob MashiahAtar LevAmos J SimonRaz SomechEtai AdamAviv BarzilaiDavid HaginShoshana Greenberger

Published in: The Journal of dermatology (2021)

Hematopoietic stem cell transplantation is the gold standard and most effective therapy for patients with DOCK8 deficiency. Dupilumab, a biological therapy indicated for atopic dermatitis and other Th2 derived dermatoses, is an excellent option for dermatitis in patients with DOCK8 deficiency and can be used as a bridge before HSCT. Larger studies are needed to confirm this observation.

Keyphrases

atopic dermatitis
replacement therapy
acute myeloid leukemia
early onset
drug induced
smoking cessation
cell therapy